Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced treatment of the first patient with an inherited metabolic disorder in a Phase 2 study of MGTA-456.
Printed from https://innovationblog.partners.org/magenta-therapeutics-announces-first-patient-transplanted-with-mgta-456-in-phase-2-study-in-inherited-metabolic-disorders · Published 07 Nov 2018
© Mass General Brigham Incorporated. All rights reserved.